Showing articles associated with Sandy Douglas
Dr Sandy Douglas is a principal investigator and academic clinician. He led the development of the large-scale manufacturing process for the Oxford-AstraZeneca COVID-19 vaccine, which has resulted in over 2 billion doses being manufactured by late 2021. Sandy is Chief Investigator of the COV008 phase I clinical trial of intranasal administration of this vaccine. He holds a Wellcome Trust Clinical Research Career Development Fellowship, is a Co-Investigator on the EPSRC funded Future Vaccine Manufacturing Research Hub (Vax-Hub) and holds an MRC grant to develop a novel rabies vaccine and carry out clinical trials.
What is your main area(s) of interest/expertise?
My main interests are the development of new antibody-inducing vaccines and breaking down the barriers to translation of new biological medicines into clinical trials and onward to real-world impact. This includes making GMP-compliant manufacturing more cost-effective and accessible to clinical academics.
What are you working on right now?
I’m Chief Investigator on three early phase clinical trials of vaccines, one on using intranasal administration of the Oxford-AstraZeneca COVID-19 vaccine, and two on rabies (one in the UK and the other in Tanzania). I’m working on improving translation of scientific discoveries to patient impact, including setting up a new team for BioProcess and Analytical Development (BiPAD) and continuing work on manufacturing processes for Adenovirus-vectored vaccines. Finally, I am working on pre-clinical development of vaccines against EBV, including the use of structural immunology to guide development of optimal immunogens.
Find out more about Sandy and his work